Treatment Strategies in Essential Thrombocythemia a critical appraisal of various experiences in different centers

References

• Murphy S. Thrombocytosis and thrombocythemia. Clin. Haematol. 1983; 12: 89–105
   PubMedGoogle Scholar
• Van Genderen P. J. J., Michiels J. J. Erythromelalgic, thrombotic and hemorrhagic manifestations in thrombocythemia. Presse Médicale 1994; 23: 73–77
   PubMed Web of Science ®Google Scholar
• Murphy S., Rosenthal D. S., Weinfeld A., Briere J., Faguet G. B., Knospe W. H., Landaw S. A., Laszlo J., Pisciotta A. V., Tartaglia A. P., Golberg J. D., Berk P. D., Donovan P. B., Wasserman L. R. Essential thrombocythemia: response during first year of therapy with Melphalan and radioactive phosphorus: a Polycythemia Vera Study Group report. Cancer Treat. Rep. 1982; 66: 1495–1500
   PubMedGoogle Scholar
• Barbui T., Cortelazzo S., Viero P., Bassan R., Dini E., Semeraro N. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. Eur. J. Cancer Clin. Oncol. 1983; 19: 1593–1599
   PubMedGoogle Scholar
• Buss D. H., Stuart J. J., Lipscomb G. E. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analyse of 129 cases. Am. J. Hematol. 1985; 20: 365–372
   PubMed Web of Science ®Google Scholar
• Bellucci S., Janvier M., Tobelem G., Flandrin G., CharpakBerger R., Boiron M. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 1986; 58: 2440–2447
   PubMed Web of Science ®Google Scholar
• Van de Pette J. E. W., Prochazka A. V., Pearson T. C., Singh A. K., Dickson E. R., Wetherley-Mein G. Primary thrombocythaemia treated with busulfan. Brit. J. Haematol 1986; 62: 229–237
   PubMed Web of Science ®Google Scholar
• Murphy S., Iland H., Rozenthal D., Lazlo J. E. T.: an interim report from the P.V.S.G. Semin. Hematol. 1986; 23: 177–182
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Jahn M., Baumann B., Kopcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 1988; 61: 2487–2496
   PubMed Web of Science ®Google Scholar
• Grossi A., Rosseti S., Vannucchi A. M., Rafanelli D., Ferrini P. R. Occurence of haemorrhagic and thrombotic events in myeloproliferative disorders. Clin. Lab. Haemat. 1988; 10: 167–175
   PubMedGoogle Scholar
• Lahuerta-Palacios J. J., Bornstein R., Fernandez-Debora F. J., Gutierrez-Rivas E., Ortiz M. C., Larregla S., Calandre L., Montero-Castillo J. Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia. Cancer 1988; 61: 1207–1212
   PubMed Web of Science ®Google Scholar
• Randi M. L., Fabris F., Rossi C., Tison T., Barbone E., Girolam A. Sex and age as prognostic factors in essential thrombocythemia. Haematologica 1992; 77: 402–404
   PubMed Web of Science ®Google Scholar
• Cortelazzo S., Viero P., Finazzi G., D'Emilio A, Rodeghiero F., Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J. Clin. Oncol. 1990; 8: 556–562
   PubMed Web of Science ®Google Scholar
• Fenaux P., Simon M., Caulier M. T., Lai J. L., Goudemand J., Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549–556
   PubMed Web of Science ®Google Scholar
• Millard F. E., Hunter C. S., Anderson M., Edelman M. J., Kosty M. P., Luiken G. A., Marino G. G. Clinical manifestations of essential thrombocythemia in young adults. Am. J. Hematol. 1990; 33: 27–31
   PubMed Web of Science ®Google Scholar
• Mc Intire K. J., Hoagland H. C., Silverstein M. N., Petit T. Essential thrombocythemia in young adults. Mayo Clin. Proc. 1991; 66: 149–154
   PubMed Web of Science ®Google Scholar
• Colombi M., Radaelli F., Zocchi L., Maiolo A. T. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991; 67: 2926–2930
   PubMed Web of Science ®Google Scholar
• Watson K. V., Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Brit. J. Haematol. 1993; 83: 198–203
   PubMed Web of Science ®Google Scholar
• Dupuy E. 1994, Personal communication.
   Google Scholar
• Turlure P., Le Prise P. Y., Letortorec S., Linassier C., Ifrah N., Desablens B., Tourani J. M., Lejeune F., Sensebe L., Briere J. B. Essential thrombocythemia (E.T.) clinical course and results of a multicenter prospective study. Blood 1993; 82(supl 1)197, (abst 775)
   Google Scholar
• Mitus A. J., Barbui T., Shulman L. N., Rosenthal D. S., Viero P., Cortelazzo S., Schafer A. I. Hemostatic complications in young patients with essential thrombocythemia. Am. J. Med. 1990; 88: 371–375
   PubMed Web of Science ®Google Scholar
• Schafer A. I. Bleeding and thrombosis in myeloproliferative disorders. Blood 1984; 64: 1–12
   PubMed Web of Science ®Google Scholar
• Budde U., Schaefer G., Mueller N., Egli H., Dent J., Ruggeri Z. M., Zimmerman T. S. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984; 64: 981–985
   PubMed Web of Science ®Google Scholar
• Budde U., Scharf R. E., Franke P., Hartman-Budde K., Dent J., Ruggeri Z. M. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993; 82: 1749–1757
   PubMed Web of Science ®Google Scholar
• Van Genderen P. J. J., Michiels J. J. van der Poel-van de Luytgaarde SCPAM., van Vliet HHDMAcquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann. Hematol. 1994; 69: 81–84
   PubMed Web of Science ®Google Scholar
• Goodman E. Hydroxyurea The Pharmacological Basis of Therapeutics. Millan Publishing Company, New York 1985; 1291–1292
   Google Scholar
• Van Genderen P. J. J., Michiels J. J. Primary thrembo-cytemia: diagnosis, clinical manifestations and management. Ann. Hematol. 1993; 67: 57–62
   PubMed Web of Science ®Google Scholar
• Tobelem G. Essential thrombocythaemia. Baillières Clin. Hematology 1989; 2: 719–728
   Google Scholar
• Lofvenberg E., Walhlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with Hydroxyurea. Eur. J. Haematol. 1988; 41: 375–381
   PubMed Web of Science ®Google Scholar
• Pearson T. C. Clinical annotation. Primary thrombocythaemia: diagnosis and management. Brit. J. Haematol. 1991; 78: 145–148
   PubMed Web of Science ®Google Scholar
• Cortelazzo S., Finazzi G., Ruggeri M., Vestri O., Galli M., Rodeghiero F., Barbui T. Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial. N. Engl. J. Med. 1995; 332: 1132–1136
   PubMed Web of Science ®Google Scholar
• Michiels J. J., Koudstall P. J., Muller A. H., van Vliet H. H. D.M. Transient neurological and occular manifestations in primary thrombocythemia. Neurology 1993; 43: 1107–1110
   PubMed Web of Science ®Google Scholar
• Scheffer M. G., Michiels J. J., Simoons M. L. Thrombocythemia and coronary artery disease. Am. Heart J. 1991; 22: 573–576
   Web of Science ®Google Scholar
• Roznan C., Giralt M., Feliu E., et al. Life expectancy of patients with chronic non leukemic myeloproliferative disorders. Cancer 1991; 67: 2658–2663
   PubMed Web of Science ®Google Scholar
• Balduini C. L., Bertolino G., Noris P., Piletta G. C. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am. J. Clin. Pathol. 1991; 95: 82–86
   PubMed Web of Science ®Google Scholar
• Murphy S., Peterson P., Iland H. J., Fruchtman S. Hydroxyurea and other myelosuppressive agents in the treatment of essential thrombocythemia: analysis of leukemogenic potential. Thromb. Haemostas. 1993; 69((suppl)), (abst.)
   Google Scholar
• Shimamoto Shibata K., Suga K., Sano M., Matzuzaki M., Ymaguchi M. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation. A brief review of recent literature. Acta. Haematol. 1994; 91: 84–88
   PubMed Web of Science ®Google Scholar
• Lofvenberg E., Nordenson I., Walhlin A. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genet. Cytogenet. 1990; 49: 57–67
   PubMed Web of Science ®Google Scholar
• Kutti J. The management of thrombocytotosis. Eur. J. Haematol. 1990; 44: 81–88
   PubMed Web of Science ®Google Scholar
• Brandt L., Anderson H. Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available?. Eur. J. Haematol. 1995; 54: 21–26
   PubMed Web of Science ®Google Scholar
• Stott H., Wallace F., Girling D. J., Stephens R. J., Galton D. A. G. Acute leukaemia after busulfan. B.M.J. 1977; 2: 1513–1517
   PubMed Web of Science ®Google Scholar
• Weinfeld A., Swolin B., Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur. J. Haematol. 1994; 52: 134–139
   PubMed Web of Science ®Google Scholar
• West W. O. Hydroxyurea in the treatment of polycythaemia vera. South Med. J. 1987; 80: 323–327
   PubMed Web of Science ®Google Scholar
• Kaplan M. E., Mack K., Goldberg J. D., Donavan P. B., Berk P. D. Long term management of polycythaemia vera with hydroxyurea: a progress report. Semin. Hematol. 1986; 23: 167–171
   PubMed Web of Science ®Google Scholar
• Nand S., Messmore H., Fisher S. G., Bird M. L., Schulz W., Fisher R. I. Leukemic transformation in polycythemia vera: analysis of risk. Am. J. Hematol. 1990; 34: 32–36
   PubMed Web of Science ®Google Scholar
• Landaw S. A. Acute leukemia in polycythaemia vera, L. R. Wasserman, P. D. Berk, N. I. Berlin. WB Saunders Company. 1995; 154–165
   Google Scholar
• Boivin P. Indications, procedure and results for the treatment of Polycythaemia vera by bleeding, pipobroman and hydroxyurea. Nouv. Rev. Ft. Hematol. 1991; 35: 491–498
   Google Scholar
• Bond W. H. Evaluation of compound 8103-Abott (N, N'-bis (3 biomopropionyl) Piperazine in patients with polycythemia vera. Proc. Am. ASDC. Cancer Res. 1962; 3: 306
   Google Scholar
• Bauters F., Jouet J. F., Goudemand M. Un traitement méconnu des polyglobulies primitives: le Pipobroman. A propos de 13 observations. Lille Médical. 1976; 202–208
   Google Scholar
• Bernard J. F., Renoux M., Dhermy D., Lallemand R., Boivin P. Traitement de la polyglobulie primitive de Vaquez par le Pipobroman. Résultats obtenus chez 63 malades traités entre 1969 et 1977. Nouv. Press. Med. 1978; 7: 3527–3530
   Google Scholar
• Bilski-Pasquier G., Blanc C. M., Bousser J. Traitement de la polycythémic de Vaquez par le 1–4-his (3 bromopropionyl Piperazine). Press. Med. 1968; 76: 1953–1956
   PubMedGoogle Scholar
• Najean Y., Dresch C., Rain J. D. Intermediate analysis of e French protocol on Polycythaemia Vera: 253 patients. Nouv. Rev. Fr. Hematol. 1991; 33: 201–203
   PubMedGoogle Scholar
• Najman A., Stachowiak J., Parlier Y., Gorin N. C., Duhamel G. Pipobroman therapy of Polycythaemia Vera. Blood 1982; 59: 890–894
   PubMed Web of Science ®Google Scholar
• Brusamolino E., Canavari A., Salvaneschi L., Merante S., Bernasconi C. Efficacy trial of Pipobroman in essential thrombocythemia: a study of 24 patients. Cancer Treat. Reports 1984; 68: 13391342
   Google Scholar
• Mazzucconi M. G., Francesconi M., Chistolini A., Falcione E., Ferrari A., Tirindelli M. C., Mandelli F. Pipobroman therapy of essential thrombocythemia. Scand. J. Haematol. 1986; 37: 306–309
   PubMedGoogle Scholar
• Bauters F., Personnal communication.
   Google Scholar
• Gisslinger H., Chott A., Scheithauer W., Gilly B., Linkesch W., Ludwig H. Interferon in essential thrombocythamia. Brit. J. Haematol. 1991; 79((suppl. 1))42–47
   PubMed Web of Science ®Google Scholar
• Giles F. J. Maintenance therapy in the myeloproliferative disorders: the current options. Brit. J. Haematol. 1991; 79((suppl. 1))92–95
   PubMed Web of Science ®Google Scholar
• Lazzarino M., Vitale A., Morra E., Gagliardi A., Bernasconi P., Torromeo C., Inverardi D., Burgio B., Castello A., Bernasconi C., Mandelli F. Interferon alpha 2b as treatment for Philadelpha-negative chronic myeloproliferative disorders with excessive thrombocytosis. Brit. J. Haematol. 1989; 72: 173–177
   PubMed Web of Science ®Google Scholar
• Turri D., Mitra M. E., Di Trapani R., Lipari M. G., Perricone R., Cajozzo A. Alpha-interferon in polycythemia vera and essential thrombocythemia. Haematologica 1991; 76: 75–77
   PubMed Web of Science ®Google Scholar
• Yataganas X., Meletis J., Plata E., Viniou N., Deligiannis F., Tsekoura C., Voscaridou E., Boussiotis V., Rombos J., Vayopoulos G., Kittas C., Fessas P. Alpha interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis. Eur. J. Cancer 1991; 27: 569–571
   Google Scholar
• Giralt M., Rubio D., Cortes M. T., San Miguel J., Steegmann J. L., SerenaFernandez J., Ranada J., Lopez-Borrasca A. Alpha interferon in the management of essential thrombocythaemia. Eur. J. Cancer 1991; 27: 572–574
   Google Scholar
• Rametta V., Ferrara F., Marottoli V., Matera C., Mettivier V., Cimino R. Recombinant interferon alpha 2b as treatment of essential thrombocythaemia. Acta Haematol. 1994; 91: 126–129
   PubMed Web of Science ®Google Scholar
• Middelhoff G., Boll I. A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia. Ann. Hematol. 1992; 64: 207–209
   PubMed Web of Science ®Google Scholar
• Sacchi S., Tabilio A., Leoni P., Riccardi A., Vecchi A., Messora C., Falzetti F., Rupoli S., Ucci G., Martelli M. F. Interferon alpha-2b in the long term treatment of essential thrombocythemia. Ann. Hematol. 1991; 63: 206–209
   PubMed Web of Science ®Google Scholar
• Han Z. C., Briere J., Abgrall J. F., Legau G., Parent D., Sensebe L. Effects of recombinant human interferon alpha on human megacaryocyte and fibroblast colony formation. Journal of biological regulators and homeostatic agents 1987; 1: 195–200
   PubMedGoogle Scholar
• Gugliotta L., Bagnara G. P., Catani L., Gaggioli L., Guarini A., Zauli G., Belmonte M. M., Lauria F., Macchi S., Tura S. In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia. Brit. J. Haematol. 1989; 71: 177–181
   PubMed Web of Science ®Google Scholar
• Bellucci S., Harousseau J. L., Brice P., Tobelem G. Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet 1988; 22: 960–961
   Google Scholar
• Kasparu H., Bernhart M., Krieger O., Lutz D. Remission may continue after termination of rIFNα-2b treatment for essential thrombocythemia. Eur. J. Haematol. 1992; 48: 33–36
   PubMed Web of Science ®Google Scholar
• Petit J. J., Callis M., Sevilla A. Normal pregnancy in a patient with essential thrombocythemia treated with interferon alpha 2b. Am. J. Hematol. 1992; 40: 80
   PubMed Web of Science ®Google Scholar
• Silverstein M. N., Petitt R. M., Solberg L. A., Fleming J. S., Knoght R. C., Schacter L. P. Anagrelide: a new drug for treating thrombocytosis. N. Engl. J. Med. 1988; 318: 1292–1294
   PubMed Web of Science ®Google Scholar
• Solberg L. A., Oles K. J., Tarach J., Silverstein M. N., Petitt R. M., et al. The effects of Anagrelid on human megakaryocytopoiesis. Blood 1989; 74((suppl. 1))10, (Abst. 62)
   Google Scholar
• Andes W. A., Noveck R. J., Fleming J. S. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb. Haemos. 1984; 52: 325–328
   PubMed Web of Science ®Google Scholar
• Mazur E. M., Rosmarin A. G., Sohl P. A., Newton J. L., Naradran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992; 79: 1931–1937
   PubMed Web of Science ®Google Scholar
• Mazzucconi M. G., De Sanctis V., Christolini A., Dragoni F., Mandelli F. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Hematologica 1992; 77: 315–317
   PubMed Web of Science ®Google Scholar
• Silverstein M. N., Petitt R. M., Solberfg L. A., Rosenbloom B., Silver R. T., et al. Anagrelide, a therapy for thrombocythemic states. Experience in 577 patients. Amer. J. Med. 1992; 92: 69–76
   PubMed Web of Science ®Google Scholar
• Silver R. T., Zaattrowski T. P., Caruso F., Chapman C., Schacter I. P., et al. Thrombocytosis refractory to hydroxyurea in chronic myeloid leukemia (CML) responds to anagrelide. Brit. J. Haemat. 1992; 80: 177, (abs. 530)
   Google Scholar
• Balduini C. L., Bertolino G., Noris P., Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferativce disorders. Haematologica 1992; 7: 740–743
   Google Scholar
• Mc Intyre K. J., Hoagland H. C., Silverstein M. N., Petitt R. M. Essential thrombocythemia in young adults. Mayo Clin. Proc. 1991; 66: 149–154
   PubMed Web of Science ®Google Scholar
• Chintagumpala M. M., Steuber C. P., Mahoney D. H., Ogden A. K., Fernbarch D. J. Essential thrombocythemia in a child: management with anagrelide. Am. J. Ped. Hematol. Oncol. 1991; 13: 52–56
   PubMedGoogle Scholar
• Murphy S., Rosenthal D. S., Weinfeld A., Briere J., Faguet G. B., Knospe W. H., Landaw S. A., Laszlo J., Pisciotta A. V., Tartaglia A. P., Golberg J. D., Berk P. D., Donovan P. B., Wasserman L. R. Essential thrombocythemia: response during first year of therapy with Melphalan and radioactive phosphorus: a Polycythemia Vera Study Group report. Cancer Treat. Rep. 1982; 66: 1495–1500
   PubMedGoogle Scholar
• De Pauw B. E., VanBergen A. N., Haanen C., Steenbergen J. Intermittent melphalan in the treatment of essential thrombocytosis with haemorrhage or thrombosis. Scand. J. Haematol. 1985; 35: 448–450
   PubMedGoogle Scholar
• Case D. C. Therapy of essential thrombocythemia with thiotepa and chlorambucil. Blood 1984; 63: 51–54
   PubMed Web of Science ®Google Scholar
• Shamasunder H. K., Gregory S. A., Knospe W. H. Uracil mustard in the treatment of thrombocytosis. Jama 1980; 244: 1454–1455
   PubMed Web of Science ®Google Scholar
• Kanoh T. Ranimustine: a new drug for treating essential thrombocythemia. Blood 1990; 76((suppl. 1))287, (abst. 1140)
   Google Scholar
• Brosdky I. Busulfan treatment of polycythaemia vera (Annotation). Brit. J. Haematol. 1982; 52: 1–6
   PubMed Web of Science ®Google Scholar